Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Page 1
Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing.
J Clin Med. 2021 Apr 4;10(7):1504. doi: 10.3390/jcm10071504.
J Clin Med. 2021.
PMID: 33916592
Free PMC article.
With current multimodality treatments, the 5-year event-free survival exceeds 80%, and 70% of patients achieve long-term "cure", hence the overall number of patients eligible for experimental drugs is small. ...
With current multimodality treatments, the 5-year event-free survival exceeds 80%, and 70% of patients achieve long-term "cure", henc …
Challenges and Opportunities for Childhood Cancer Drug Development.
Houghton PJ, Kurmasheva RT.
Houghton PJ, et al. Among authors: kurmasheva rt.
Pharmacol Rev. 2019 Oct;71(4):671-697. doi: 10.1124/pr.118.016972.
Pharmacol Rev. 2019.
PMID: 31558580
Free PMC article.
Review.
However, for patients surviving their malignancy, therapy-related long-term adverse effects are severe, with an estimated 50% having chronic life-threatening toxicities related to therapy in their fourth or fifth decade of life. ...
However, for patients surviving their malignancy, therapy-related long-term adverse effects are severe, with an estimated 50% having …
Item in Clipboard
Identifying novel therapeutic agents using xenograft models of pediatric cancer.
Kurmasheva RT, Houghton PJ.
Kurmasheva RT, et al.
Cancer Chemother Pharmacol. 2016 Aug;78(2):221-32. doi: 10.1007/s00280-016-3042-6. Epub 2016 May 18.
Cancer Chemother Pharmacol. 2016.
PMID: 27193096
Free PMC article.
Review.
However, current approaches to curative therapy result in significant morbidity and long-term sequelae, including cardiac dysfunction and cognitive impairment. ...
However, current approaches to curative therapy result in significant morbidity and long-term sequelae, including cardiac dysfunction …
Item in Clipboard
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation.
Geier B, Kurmashev D, Kurmasheva RT, Houghton PJ.
Geier B, et al. Among authors: kurmasheva rt.
Front Oncol. 2015 Aug 26;5:193. doi: 10.3389/fonc.2015.00193. eCollection 2015.
Front Oncol. 2015.
PMID: 26380223
Free PMC article.
Review.
However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. ...
However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidi …
Item in Clipboard
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
Studebaker A, Bondra K, Seum S, Shen C, Phelps DA, Chronowski C, Leasure J, Smith PD, Kurmasheva RT, Mo X, Fouladi M, Houghton PJ.
Studebaker A, et al. Among authors: kurmasheva rt.
Pediatr Blood Cancer. 2015 Oct;62(10):1768-74. doi: 10.1002/pbc.25579. Epub 2015 May 15.
Pediatr Blood Cancer. 2015.
PMID: 25981859
Free PMC article.
Patients with recurrent low-grade tumors or anaplastic astrocytoma may receive radiation treatment; however, the long-term sequellae from radiation treatment can be severe. As many childhood gliomas are associated with activation of BRAF, we have explored the combination o …
Patients with recurrent low-grade tumors or anaplastic astrocytoma may receive radiation treatment; however, the long-term sequellae …
Item in Clipboard
Cite
Cite